Exelixis Slides 2% After FDA Delays Colon Cancer Decision

Exelixis (EXEL) fell 2.00% to 56.28 on Friday, Sept. 11, 2026, after the FDA delayed a decision on its colon cancer candidate zanzalintinib, pushing the IBD 50 stock out of a technical buy zone.

Exelixis (EXEL) fell on Friday after the Food and Drug Administration pushed back its decision on the company's experimental colon cancer treatment, an unexpected regulatory detour that knocked the stock out of the technical buy zone chart-watchers had been tracking.

The shares were quoted at 56.28 as of 15:28 GMT on Friday, Sept. 11, 2026, down 2.00% from the prior close of 57.43. The day's range ran from 54.55 to 57.44, meaning the stock was already trading near its session high before the news landed and then gave up that ground quickly. From the intraday low back to the last print, the stock had clawed back roughly 3.2% — an illustrative move based on the quoted range, not a reported figure — which suggests buyers were willing to step in once the initial selling exhausted itself.

What makes the drop conspicuous is the tape around it. The broad market was strong: the S&P 500 proxy SPY rose 1.11% to $766.25, the Nasdaq 100 proxy QQQ added 1.23% to $717.38 and the Dow 30 proxy DIA gained 1.06% to $526.25. Against a market up more than a percent, Exelixis was down two — a relative gap of about 3.1 percentage points on the day by that illustrative comparison. Single-stock regulatory news cuts through index strength in a way few other catalysts do.

A scheduling delay, not a rejection

The distinction matters and it is the first thing holders should fix on. A delay to a PDUFA date — the deadline the FDA sets itself under the Prescription Drug User Fee Act to rule on a marketing application — is a change to the calendar, not a verdict on the drug. The agency routinely extends its own review clocks when it wants more time with a submission, and those extensions are not, on their own, a statement that the application is deficient.

Markets nonetheless price delays as bad news, for two reasons that have nothing to do with the science. The first is time value: every quarter that a launch slips is a quarter of revenue moved further out and discounted harder. The second is information asymmetry. Investors do not know what prompted the extension, so they assume the least convenient explanation until told otherwise. That is the behavioural mechanism behind Friday's decline.

The treatment at the centre of the delay is zanzalintinib, the candidate identified in Investor's Business Daily's report on the move, which is being advanced in colorectal cancer. Exelixis has not, on the facts available, had its application turned down; what has changed is when a ruling arrives.

Why colorectal cancer is the pipeline question

Colorectal cancer is one of oncology's largest and most stubbornly under-served indications, particularly in later lines of therapy where patients have already cycled through chemotherapy and the options thin out fast. For a mid-cap oncology company, an approval in that setting is not an incremental line item — it is the kind of label that changes the shape of the revenue base and gives a commercial organisation a second product to sell into the same prescriber network it already calls on.

That is precisely why the delay bites harder than a two-percent move might suggest. Analysts building forward models for a company like Exelixis typically anchor the out-years to a launch date. Move the date and every downstream assumption — sales ramp, peak share, the year the new product overtakes the legacy franchise — shifts with it. None of those numbers can be stated here because none have been reported, but the mechanical consequence is not in dispute: later approval means later revenue.

The offsetting point is that Exelixis is not a single-asset story waiting on one FDA letter to justify its market value. It is a commercial-stage oncology company with an existing revenue engine, which is part of why the stock recovered a good portion of its intraday loss rather than collapsing. Binary-risk biotechs do not typically trade back up off the low on a day like this.

The technical damage and the IBD 50 context

Exelixis carries a place on the IBD 50, a screen that selects for companies combining earnings and sales momentum with relative price strength. Membership in that kind of list creates its own reflexive dynamic. Momentum-oriented buyers use defined entry ranges — a buy zone above a chart pivot — and they sell mechanically when the stock closes back below it. Friday's drop out of that zone therefore triggers a second wave of supply that has nothing to do with anyone's view on colorectal cancer biology.

Technically, the shape of the session is the useful signal. Trading up to 57.44 and then down to 54.55 before settling at 56.28 is a wide, high-volume-looking reversal bar, the sort of print that typically needs several sessions to resolve. Traders will watch whether the stock can reclaim the level it broke, and whether the 54.55 low holds on any retest. A stock that undercuts its reversal low is usually telling you the sellers are institutional; one that holds it is telling you the flush was mechanical.

What to watch from here

Three things will determine whether Friday reads as noise or as the start of a de-rating.

• The new decision date. The length of the extension is the single most important missing fact. A short procedural push is a very different proposition from an extension tied to a request for additional data.
• The stated reason. Whether the FDA sought more information, flagged manufacturing or inspection items, or simply needed more review time frames the entire risk picture. Until that is public, the stock trades on assumption.
• Price behaviour around 54.55 and 57.43. Reclaiming the prior close restores the momentum case. Losing the session low invites a deeper unwind from the same funds that bought the breakout.

For long-term holders, a calendar change to a pending oncology approval is rarely a thesis-breaking event. For the momentum money that owns the stock because it was in a buy zone, the thesis was the buy zone — and that is what broke on Friday. The split between those two constituencies is why a stock can fall 2% on news that, on its face, changes nothing about whether a drug works.

All prices cited are intraday as of 15:28 GMT on Sept. 11, 2026, with the market open.

Key facts

• Stock: Exelixis (EXEL) at 56.28, down 2.00%, as of 15:28 GMT Sept. 11, 2026
• Session range: 54.55 to 57.44; previous close 57.43
• Catalyst: FDA delayed its decision on colon cancer candidate zanzalintinib
• Market backdrop: S&P 500 proxy SPY +1.11% at $766.25; Nasdaq 100 proxy QQQ +1.23%

Frequently asked questions

How far did Exelixis stock fall?

Exelixis (EXEL) was quoted at 56.28 as of 15:28 GMT on Friday, Sept. 11, 2026, down 2.00% from the previous close of 57.43. The stock traded as high as 57.44 and as low as 54.55 during the session, so it recovered a meaningful part of its intraday loss before the last print.

What is a PDUFA date and why does a delay move a stock?

A PDUFA date is the deadline the FDA sets itself to rule on a drug marketing application under the Prescription Drug User Fee Act. A delay is a change to that calendar, not a rejection. Markets sell it anyway because revenue is pushed further out and because investors do not initially know why the agency needed more time.

Which drug is affected?

The candidate at the centre of the delay is zanzalintinib, which Exelixis is developing in colorectal cancer. The FDA has pushed back its decision on the application rather than turning it down. The specific length of the extension and the agency's stated reason were not disclosed in the initial report of the delay.

What does the IBD 50 buy zone reference mean?

The IBD 50 is a screen of companies combining earnings and sales momentum with relative price strength. Momentum investors buy such stocks within a defined range above a chart pivot and sell mechanically when the price falls back below it. Exelixis dropped out of that zone Friday, which triggers technical selling independent of the drug news.

Was the broader market weak on the same day?

No — the decline was stock-specific. The S&P 500 proxy SPY rose 1.11% to $766.25, the Nasdaq 100 proxy QQQ gained 1.23% to $717.38, and the Dow 30 proxy DIA added 1.06% to $526.25. Exelixis fell 2.00% against that strength, which is why the move stood out.

What should investors watch next?

Three items: the new FDA decision date, which shows how long the slip is; the stated reason for the extension, which separates a procedural push from a request for more data; and the stock's behaviour around the 54.55 session low and the 57.43 prior close, which will show whether the selling was mechanical or institutional.

Sources

• Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay — Investors Business Daily

Photo: https://kaboompics.com/ · Pexels Licence — source